PTC Therapeutics (NASDAQ: PTCT) gives 2025 preview and 2026 outlook

Rhea-AI Filing Summary

PTC Therapeutics released preliminary, unaudited 2025 figures and issued 2026 guidance. For the year ending December 31, 2025, it expects to report total net product and royalty revenue of approximately $823.4 million, including total net product revenue of about $587.8 million and net product revenue for Sephience™ (sepiapterin) of roughly $112.1 million. Final results will follow completion of the year-end audit.

For 2026, the company anticipates full-year total product revenues of $700 million to $800 million, excluding Evrysdi® royalty and collaboration revenue. It projects GAAP R&D and SG&A expenses of $775 million to $815 million and non-GAAP R&D and SG&A expenses of $680 million to $720 million, excluding an estimated $95 million of non-cash stock-based compensation. PTC plans to discuss these figures and 2026 milestones at the J.P. Morgan Healthcare Conference and then enter an investor quiet period.

Insights

Biopharma financial analyst

PTC shares sizeable 2025 revenue preview and detailed 2026 expense and product revenue guidance.

PTC Therapeutics is signaling scale through its preliminary 2025 numbers, with total net product and royalty revenue of about $823.4 million and net product revenue of roughly $587.8 million. The disclosure that Sephience™ contributes around $112.1 million highlights its role within the product portfolio. These figures remain subject to the completion of the year-end audit, so they could change.

The 2026 outlook frames expectations for both growth and spending. The company guides to total product revenues of $700 million to $800 million, excluding Evrysdi® royalties and collaboration revenue, which focuses attention on its directly controlled product base. On the cost side, GAAP R&D and SG&A of $775 million to $815 million versus non-GAAP of $680 million to $720 million underscores the impact of an estimated $95 million in non-cash stock-based compensation. Upcoming commentary at the January 12, 2026 J.P. Morgan Healthcare Conference will give management a platform to explain how these spending plans support the 2026 milestones they highlight.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001070081false00010700812026-01-122026-01-12

​

​

UNITED STATES

​

SECURITIES AND EXCHANGE COMMISSION

​

WASHINGTON, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

​

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): January 12, 2026

​

PTC THERAPEUTICS, INC.

​

(Exact Name of Company as Specified in Charter)

​

​	​	​	​	​
Delaware	​ ​ ​	001-35969	​ ​ ​	04-3416587
(State or Other Jurisdiction	​	(Commission	​	(IRS Employer
of Incorporation)	​	File Number)	​	Identification No.)

​

​

​	​	​	​
500 Warren Corporate Center Drive	​	​ ​ ​	​
Warren, NJ	​	​	07059
(Address of Principal Executive Offices)	​	​	(Zip Code)

​

Registrant’s telephone number, including area code: (908) 222-7000

​

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of each exchange on which registered
Common Stock, $0.001 par value per share	​	PTCT	​	Nasdaq Global Select Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 2.02. Results of Operations and Financial Condition.

On January 12, 2026, PTC Therapeutics, Inc. (the “Company”) issued a press release (the “press release”) announcing certain preliminary (unaudited) financial information for its fiscal year ending December 31, 2025, including that the Company expects to report (i) total unaudited net product and royalty revenue of approximately $823.4 million, (ii) total unaudited net product revenue of approximately $587.8 million, and (iii) unaudited net product revenue for Sephience™ (sepiapterin) of approximately $112.1 million. Final results are subject to completion of the Company’s year-end audit.

Item 7.01. Regulation FD Disclosure.

On January 12, 2026, the Company also announced financial guidance for its fiscal year ending December 31, 2026 in the press release, including that the Company anticipates (i) full year total product revenues of $700 million to $800 million, excluding Evrysdi^® (risdiplam) royalty revenue and collaboration revenue and (ii) GAAP R&D and SG&A expense for the full year 2026 of $775 million to $815 million with non-GAAP R&D and SG&A expense for the full year 2026 of $680 million to $720 million, excluding estimated non-cash, stock-based compensation expense of $95 million.

The Company announced that on Monday, January 12, 2026 at 12:00 p.m. EST at the 44th Annual J.P. Morgan Healthcare Conference (the “Conference”), the Company will provide an update on 2025 accomplishments and highlight upcoming 2026 potential value-creating milestones. The Company will also present its preliminary 2025 unaudited financial results and 2026 financial guidance. The presentation will be webcast live on the Events and Presentations page under the Investors section of the Company’s website. Following the completion of the Conference, the Company will enter an investor quiet period until it provides its next corporate update.

A copy of the press release and the slide presentation are attached to this Current Report on Form 8-K as Exhibits 99.1 and 99.2 and are incorporated by reference into this Item 7.01.

This Current Report on Form 8-K and Exhibits 99.1 and 99.2 include a forward-looking financial measure that was not prepared in accordance with accounting principles generally accepted in the United States (GAAP), non-GAAP R&D and SG&A expenses (which excludes non-cash stock-based compensation expense). Management uses this measure when assessing and identifying operational trends and, in management’s opinion, this non-GAAP measure is useful to investors and other users of its financial statements by providing greater transparency into the historical and projected operating performance of the Company and the Company’s future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP.

The information set forth in or incorporated by reference into Item 2.02 or this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Current Report on Form 8-K or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Current Report on Form 8-K.

Forward Looking Statements: All statements, other than those of historical fact, contained in this Current Report on Form 8-K, are forward-looking statements, including reporting expectations with respect to financial information for fiscal year 2025 and financial guidance for fiscal year 2026. The Company's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to the preliminary nature of the Company's 2025 financial information, which is subject to completion of the Company's year-end audit; the assumptions underlying the Company's financial guidance for 2026; and the factors discussed in the “Risk Factors” section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as well as any updates to these risk factors filed from time to time in the Company's other filings with the Securities and Exchange Commission. You are urged to carefully consider all such factors. The forward-looking statements contained herein and the exhibits hereto represent the Company's views only as of the date of this Current Report on Form 8-K and the Company does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this Current Report on Form 8-K except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

​	​	​
Exhibit No.	​ ​ ​	Description
99.1	​	Press Release, dated January 12, 2026 issued by PTC Therapeutics, Inc.
99.2	​	Corporate Presentation – 44th Annual J.P. Morgan Healthcare Conference
104	​	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

​

​

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​
​	PTC Therapeutics, Inc.
​	​
Date: January 12, 2026	By:	/s/ Pierre Gravier
​	Name:	Pierre Gravier
​	Title:	Chief Financial Officer

​

​

FAQ

What preliminary 2025 revenue did PTC Therapeutics (PTCT) disclose?

PTC Therapeutics expects to report 2025 total unaudited net product and royalty revenue of approximately $823.4 million. Within this, total net product revenue is projected at about $587.8 million, and net product revenue for Sephience™ (sepiapterin) at roughly $112.1 million, all subject to completion of the year-end audit.

What is PTC Therapeutics’ 2026 total product revenue guidance?

For 2026, PTC Therapeutics anticipates full-year total product revenues of $700 million to $800 million, explicitly excluding Evrysdi® (risdiplam) royalty revenue and collaboration revenue from this range.

What 2026 GAAP and non-GAAP expense guidance did PTCT provide?

The company projects 2026 GAAP R&D and SG&A expenses of $775 million to $815 million. It also provided non-GAAP R&D and SG&A guidance of $680 million to $720 million, which excludes estimated non-cash stock-based compensation expense of $95 million.

How does PTC Therapeutics define its non-GAAP R&D and SG&A measure?

PTC’s non-GAAP R&D and SG&A measure excludes non-cash stock-based compensation expense. Management states it uses this measure to assess operational trends and believes it provides investors greater transparency into historical and projected operating performance and the company’s future outlook.

What event will PTC Therapeutics use to discuss its 2025 results and 2026 guidance?

On January 12, 2026 at 12:00 p.m. EST, PTC Therapeutics plans to present at the 44th Annual J.P. Morgan Healthcare Conference, where it will review 2025 accomplishments, outline potential 2026 milestones, and discuss preliminary 2025 unaudited financial results and 2026 financial guidance. The presentation will be webcast on its investor website.

Will the information in this 8-K be treated as filed with the SEC?

The company states that the information in Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into Securities Act or Exchange Act filings, except where specifically referenced.